Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism

Journal of Clinical Pharmacology - Tập 61 Số 2 - Trang 172-180 - 2021
Bharat Damle1, Frank C. Jen1,2, Nancy Sherman3, Darshana Jani4, Kevin Sweeney5
1Clinical Pharmacology, Pfizer Inc., New York, New York, USA
2This applies to Frank Jen. He was with Pfizer at the time of study conduct. Now retired.
3Global Product Development, Pfizer Inc, New York, New York, USA
4Clinical Pharmacology, Pfizer Inc., Cambridge, Massachusetts, USA
5Clinical Pharmacology, Pfizer Inc., Groton, Connecticut, USA

Tóm tắt

AbstractThis article describes the population pharmacokinetics (PK) of dalteparin in pediatric patients with venous thromboembolism (VTE). A prospective multicenter open‐label study was conducted in children who required anticoagulation for the treatment of VTE. The study population included children with and without cancer. The goal was to describe the pharmacokinetics of dalteparin using anti‐Xa as a surrogate marker and to determine the dose required to achieve therapeutic anti‐Xa levels (0.5‐1.0 IU/mL). The anti‐Xa data were supplemented with 2 published studies and analyzed using population pharmacokinetic approaches. The pharmacokinetics of dalteparin following subcutaneous injection in pediatric patients was described by a 1‐compartment model with linear absorption and elimination. Body weight was added as a covariate on both CL/F and Vd/F as a power function with fixed exponents of 0.75 and 1.0, respectively. The estimates of CL/F and Vd/F in the full model were 929 mL/h and 7180 mL, respectively, for a reference female patient aged 12 years with body weight of 43 kg. Body weight‐normalized CL/F decreased with age. Cancer status and sex did not have significant effects on CL/F and Vd/F. Simulations were conducted to select starting doses of dalteparin that would rapidly achieve therapeutic anti‐Xa levels. These simulations suggested that the recommended starting doses of dalteparin administered subcutaneously in pediatric patients of different age cohort groups for treatment of VTE were 150 IU/kg every 12 hours (1 month to <2 years), 125 IU/kg every 12 hours (≥2 to <8 years), and 100 IU/kg every 12 hours (≥8 to <19 years).

Từ khóa


Tài liệu tham khảo

10.2165/00003495-199652020-00011

Fragmin (dalteparin sodium) US package insert.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020287s072lbl.pdf. Published June 2017. Accessed August 14 2020.

10.1056/NEJMoa025313

10.1097/BPB.0000000000000053

10.1016/j.hoc.2009.11.005

10.4103/0976-0105.134947

10.3389/fped.2017.00026

10.1182/blood-2015-06-651539

10.1378/chest.11-2308

10.1182/asheducation.V2012.1.439.3798661

10.1007/PL00014339

10.1111/jth.12716

10.1016/j.thromres.2015.05.017

10.1056/NEJM199709043371007

Jeske W, 1999, In vitro studies on biochemistry and pharmacology of low molecular weight heparins, Semin Thromb Hemost, 3, 27

10.1161/CIRCULATIONAHA.104.478222

Fragmin for the treatment of acute VTE in pediatric cancer patients.https://clinicaltrials.gov/ct2/show/NCT00952380. Accessed August 14 2020.

Barrett JS, 2008, A population‐based analysis of dalteparin pharmacokinetics in pediatric patients at risk for thromboembolic events. Abstract thirty‐seventh annual meeting American College of Clinical Pharmacology 14–16 Sep 2008; Philadelphia, Pennsylvania, J Clin Pharmacol, 48, 1099, 10.1177/00912700080480091001

Thông tin
Thông tin xuất bản

Journal of Clinical Pharmacology

Tập 61 Số 2

172-180

Thông tin tác giả